All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Treatments for systemic mastocytosis: Latest updates from IACH
Bookmark this article
|
SM is a very rare, multifunctional, and multiorgan disorder and can be classified as non-advanced or advanced, with the overall life expectancy being linked to this classification.1 C-KIT D816V driver mutations are present in >90% of cases, as such KIT-targeting TKIs are promising therapeutic options for this patient population.1 During the 7th Annual Meeting of the IACH, Radia provided an overview of the current treatment landscape of SM, with a focus on advanced SM, and discussed treatment options such as KIT-targeting TKI inhibitors and allo-HSCT.1
|
| Key learnings |
| Currently, two KIT-targeted agents, midostaurin and avapritinib, are approved for the treatment of SM, and avapritinib is the only agent approved for ISM. A further two agents, bezuclastinib and elenestinib, are being investigated in phase II clinical trials. |
| The 3-year updated results from the multicenter, open-label, phase II PATHFINDER trial (NCT03580655) of avapritinib demonstrated a rapid and durable response rate of 75% across all advanced SM subtypes, with an ORR of 90% and 73% in treatment-naïve and previously treated patients, respectively. |
| Preliminary data from the ongoing, open-label, multicenter, phase II APEX trial (NCT04996875) showed that bezuclastinib treatment resulted in a reduction of serum tryptase, bone marrow mast cell burden, and KIT D816V VAF in patients with advanced SM. |
| The majority of patients who progress after treatment with KIT inhibitors show presence of SM-AHN. This highlights the limitations of KIT monotherapy in a genetically complex disease. Several trials are evaluating the potential role of combination therapies, such as bezuclastinib plus HMA (APEX; NCT04996875), elenestinib plus HMA (AZURE; NCT05609942), and avapritinib plus decitabine (NCT06327685). |
| The EBMT Practice Harmonization and Guidelines provide an up-to-date framework to guide allo-HSCT in patients with advanced SM. In addition, with the advancements in KIT-targeting TKIs, treatment goals may evolve to focus on MRD negativity, treatment-free remission, combination therapies, preventing AHN progression to AML, and KIT inhibition in the peri-transplant setting. |
Abbreviations: AHN, associated hematologic neoplasm; allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; EBMT, European Society for Blood and Marrow Transplantation; HMA, hypomethylating agent; IACH, International Academy for Clinical Hematology; ISM, indolent systemic mastocytosis; MRD, measurable residual disease; ORR, overall response rate; SM, systemic mastocytosis; TKI, tyrosine kinase inhibitor; VAF, variant allele frequency.
- Radia DH. Systemic mastocytosis: Updates in clinical trials. Presented at: 7th Annual Meeting of the International Academy for Clinical Hematology; Sep 19-21, 2024; Paris, FR.
Your opinion matters
26 votes - 21 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox